TEST:

MammaPrint

P3, N=1520, Not yet recruiting, West German Study Group

Innovative approaches such as liquid biopsy and next-generation sequencing (NGS) enable minimally invasive monitoring and personalized care, especially in advanced disease. Breast cancer pathology is thus a dynamic, integrative discipline central to precision oncology, driven by ongoing technological and molecular advances, and essential to multidisciplinary cancer care.

Prognostic evaluation in the external cohort exhibits significant stratification of distant metastasis risk (HR: 3.14, p-value = 0.0014), underscoring the prognostic power of CPMP. These findings demonstrate the capability of CPMP in MP risk prediction, offering a flexible supplement to genomic risk assessment in early-stage BC.

High HER2 intensity and HER2 intrinsic subtype could be a means for predicting achievement of pCR. The findings indicate the essential role of MP/BP subtyping in the treatment of HER2 + BC.

Multi-gene expression assays have reshaped precision oncology in breast cancer by enabling more individualized therapy and supporting de-escalation strategies. Future integration with multi-omics data, development of novel predictive assays, and expansion of validation in diverse populations are essential to maximize their global clinical utility.

A novel baseline response index combining CCL4 and pRb showed excellent predictive performance and stratified patients by likelihood of clinical benefit, with ctDNA dynamics further refining stratification. These findings support DAL-AI as a promising neoadjuvant option and highlight the value of biomarker-guided strategies for treatment optimization.

49. See the NIHR Funding and Awards website for further award information.

The predictive model fitted using Firth's penalized logistic regression demonstrated an adequate discriminative ability (AUC = 0.755). MMP was the variable with the greatest weight, followed by RT. These variables allow for a more accurate prediction of recurrence risk than traditional clinicopathological factors, supporting their value in the personalization of treatment. This study reports statistically significant differences when comparing the group without radiotherapy (BED = 0 Gy) to the low-dose group (BED < 60 Gy), with a p-value of 0.0475.

Thematic analysis highlights the importance of integrating psychological support, patient education, and counseling throughout the genomic testing process. This review emphasizes the need for a holistic, patient-centered approach that addresses the emotional and cognitive consequences of precision oncology and identifies key areas for future psychosocial intervention research.

P2, N=70, Recruiting, Criterium, Inc. | Trial completion date: Dec 2027 --> Dec 2028

P=N/A, N=1151, Completed, AstraZeneca | N=2700 --> 1151 | Trial completion date: Oct 2025 --> May 2025 | Trial primary completion date: Oct 2025 --> May 2025 | Recruiting --> Completed

In the early setting, neoadjuvant chemo-immunotherapy with nivolumab or pembrolizumab increased the rate of complete responses compared to chemotherapy alone. However, this systematic review is limited by study heterogeneity and the inclusion of ongoing or immature trials, which prevents quantitative analysis and may affect future conclusions on ICIs in HR+/HER2- breast cancer. Finally, optimized combination strategies could enhance tumor immunogenicity, while predictive biomarkers such as PD-L1, TILs, or specific genomic signatures could identify responsive patients.